In terms of medication, we believe that inhibition of the IL‐6/JAK2/STAT3 signaling pathway is a viable research direction, and related inhibitors have the potential to be used in the treatment of PCM to assist the current surgical treatment with high recurrence rate. This evidence concerns the gene JAK2 and paracoccidioidomycosis.